The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study

Kevin Ke; Krishna Pillai; Ahmed H Mekkawy; Javed Akhter; Samina Badar; Sarah J Valle; David L Morris

doi:10.1007/s12672-021-00418-5

The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study

Discov Oncol. 2021 Aug 16;12(1):25. doi: 10.1007/s12672-021-00418-5.

Authors

Kevin Ke^{1

2}, Krishna Pillai^{1

2}, Ahmed H Mekkawy^{1

2}, Javed Akhter^{1

2}, Samina Badar^{1

3}, Sarah J Valle^{1

2}, David L Morris^{4

5

6}

Affiliations

¹ Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia.
² Mucpharm Pty Ltd, Kogarah, NSW, 2217, Australia.
³ St George & Sutherland Clinical School, University of New South Wales, Sydney, NSW, 2217, Australia.
⁴ Department of Surgery, St. George Hospital, Kogarah, NSW, 2217, Australia. david.morris@unsw.edu.au.
⁵ Mucpharm Pty Ltd, Kogarah, NSW, 2217, Australia. david.morris@unsw.edu.au.
⁶ St George & Sutherland Clinical School, University of New South Wales, Sydney, NSW, 2217, Australia. david.morris@unsw.edu.au.

Abstract

Intraperitoneal administration of BromAc (bromelain + acetylcysteine) is currently undergoing a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on analysis of routine blood parameters before and after treatment for a series of 25 patients in this trial. Blood parameters assessed included full blood count, electrolytes, urea, and creatinine, liver function tests, coagulation studies, as well as inflammatory markers (CRP). Certain parameters such as CRP, and white cell count, were significantly elevated after treatment whilst serum albumin level was reduced indicating an inflammatory reaction. However, liver enzymes, coagulation studies, and other parameters were not affected. Therefore, there are no additional safety signals evident upon analysis of routine blood parameter testing.

Keywords: Acetylcysteine; Blood; BromAc®; Bromelain; PMP; Pseudomyxoma peritonei.